SCHEMBL25403240

SCHEMBL25403240

Cc1ccc(-c2ncc(Br)s2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.42
MAPT P10636 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 2/20 0.41
CYP17A1 P05093 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.34
FBP1 P09467 4/20 0.33
ALDH1A1 P00352 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
POLQ O75417 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
NPC1 O15118 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509373 0.86 SNCA (0.42) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL20641436 0.83 SNCA (0.41) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL20645325 0.81 SNCA (0.39) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL25400693 0.80 ALDH1A3 (0.38) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL25402313 0.80 SNCA (0.41) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL25405292 0.80 HSD17B1 (0.41) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL4051328 0.76 CYP17A1 (0.36) SNCAMAPTKDM4EMEN1KMT2A
SCHEMBL2093617 0.76 L3MBTL1 (0.41) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL20641410 0.71 KDM4E (0.66) MAPTKDM4EHPGDLMNATP53
SCHEMBL10013471 0.71 SNCA (0.51) SNCAMAPTFBP1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 US disclosed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 US disclosed
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED 2024-01-18 US disclosed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 WO disclosed
WO-2023172957-A1 THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2023-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018136-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 SNCA 4826/4885MAPT 1795/4885KDM4E 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.